The Clinical and Pathological Characteristics That Differentiate Cases With “Low Estrogen Receptor Expression” From Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

The Clinical and Pathological Characteristics That Differentiate Cases With “Low Estrogen Receptor Expression” From Triple-Negative Breast Cancer

Published:2024-01-01 Issue:1 Volume:20 Page:19-24
ISSN:2587-0831
Container-title:European Journal of Breast Health
language:
Short-container-title:EJBH

Author:

Karaali Cem^ORCID,Emiroğlu Mümin^ORCID,Değirmenci Mustafa^ORCID,Keser Murat^ORCID,Salimoğlu Semra^ORCID,Kelten Talu Canan^ORCID

Publisher

Galenos Yayinevi

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Internal Medicine,Surgery

Reference14 articles.

1. 1. WHO Classification of Tumours Editorial Board. Breast tumours. Lyon (France): International Agency for Pesearch on Cancer; 2019. (WHO classification of tumours series, 5th ed. 2). https://publications.iarc.fr/581. [Crossref]

2. 2. Özmen V, Özmen T, Doğru V. Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. Eur J Breast Health 2019; 15: 276. (PMID: 31620689) [Crossref]

3. 3. Paakkola NM, Karakatsanis A, Mauri D, Foukakis T, Valachis A. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. ESMO Open 2021; 6: 100289. (PMID: 34678571) [Crossref]

4. 4. Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat 2021; 188: 225-235. (PMID: 33694051) [Crossref]

5. 5. Dieci MV, Griguolo G, Bottosso M, Tsvetkova V, Giorgi CA, Vernaci G, et al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer 2021; 7: 101. (PMID: 34341356) [Crossref]